- $3.57bn
- $3.08bn
- $517.15m
U.S. STOCKS ON THE MOVE-Boston Beer, GE Vernova, Absci Corp
U.S. STOCKS ON THE MOVE-HCA Healthcare, Phillips 66, Booz Allen
U.S. STOCKS ON THE MOVE-Estee Lauder, Coursera, Paramount
Veracyte jumps after diagnostics company to join S&P 600 Small Cap Index
Veracyte Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Veracyte Q1 Revenue USD 114.5 Million Vs. IBES Estimate USD 111.1 Million
Brief: Veracyte Announces Expanded Availability Of Decipher Prostate Test To Patients With Metastatic Prostate Cancer
Brief: New Data Demonstrate Accuracy Of Veracyte's Whole-Genome Sequencing-Based Mrd Testing Platform For Muscle-Invasive Bladder Cancer
Brief: Veracyte's Decipher, MRD tests highlights to be presented at EAU25
Veracyte Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Veracyte’S Decipher Prostate Test Is Now The Only Gene Expression Test Recommended In Nccn® Prostate Cancer Guidelines
Veracyte Inc reports results for the quarter ended in January 1 - Earnings Summary
Brief: Veracyte Q3 Revenue USD 115.9 Million Vs. IBES Estimate USD 109.8 Million
Brief: Veracyte Says Decipher Prostate Test Predicts Chemotherapy Benefit In Patients With Metastatic Prostate Cancer
Brief: Veracyte Appoints Brent Shafer And Tom Miller, To Its Board
U.S. STOCKS ON THE MOVE-Abbott Laboratories, Medtronic, Axon
U.S. STOCKS ON THE MOVE-Abbott Laboratories, Medtronic, Axon
Veracyte rises after FY revenue forecast uplift
Veracyte Inc reports results for the quarter ended in June - Earnings Summary